Revolution Medicines Inc. Common Stock vs Trip.com Group Ltd — how do they compare? Revolution Medicines Inc. Common Stock trades at $189.1 (market cap $40.32B), while Trip.com Group Ltd trades at $38.66 (market cap $23.75B). The key difference: Revolution Medicines Inc. Common Stock is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 0 Days and Trip.com Group Ltd for 79 Days on average.
| RVMD | TCOM | |
|---|---|---|
Market Cap | $40.32B | $23.75B |
Volume | 4,855,734 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $221.15 | $78.96 |
52-Week Low | $47.50 | $37.96 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $37.02B | $15.91B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Trip.com Group (TCOM) trades at $38.09, down 0.44% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamentals with revenue growth from $53.3B in 2024 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations with $1.07 EPS versus $0.98 expected, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The investment outlook remains positive given attractive valuations (P/E 7.36, EV/EBITDA 3.55) and analyst consensus price target of $56.64 representing 49% upside. However, regulatory risks and competitive pressures from dismantled ranking algorithms require monitoring. With 70% analyst buy ratings and strong cash flow generation, TCOM offers value for patient investors despite near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →